ENVALITH
キッセイ薬品工業株式会社 logo

KISSEI PHARMACEUTICAL CO., LTD.

4547・Prime Market・Pharmaceuticals

キッセイ薬品工業株式会社 logo
KISSEI PHARMACEUTICAL CO., LTD.4547

Governance

The company has adopted a Board of Corporate Auditors structure, comprising 12 directors (including 4 outside directors) and 4 corporate auditors (including 2 outside auditors). As advisory bodies to the Board of Directors, it has established a Nomination and Compensation Deliberation Committee, a Risk Management Committee, a Compliance Committee, and a Sustainability Promotion Committee, aiming to enhance management transparency and oversight functions.

Nomination Committee

Established

Compensation Committee

Established

Risk Management

The company has established a Risk Management Committee and a Compliance Committee as advisory bodies to the Board of Directors, building a company-wide risk management framework based on the "Risk Management Regulations." Sustainability-related risks are evaluated at least once a year by the Sustainability Promotion Committee, and a system has been put in place to deliberate and report on these matters to the Board of Directors and the Board of Corporate Auditors.

Shareholder Returns

Under a progressive dividend policy, the annual dividend for FY2026 (ending March 2026) is planned at ¥160 per share (interim ¥60 + year-end ¥100, including a ¥40 commemorative dividend for the 80th anniversary of the company's founding), with a payout ratio of 48.3%. For FY2027 (ending March 2027), an annual dividend of ¥170 (interim ¥105 + year-end ¥65) is planned. Under the 5-year medium-term plan "Beyond 80," total dividends of ¥27.0 billion and total share buybacks of ¥30.0 billion (approximately ¥6.0 billion annually) are planned.

Dividend Policy

The basic policy is to maintain stable dividends, aiming for a payout ratio of 40% or more while implementing progressive dividends (ordinary dividends). Dividends are paid twice a year, interim and year-end. Under the 5-year medium-term management plan "Beyond 80," total dividends of ¥27.0 billion are planned. To mark the 80th anniversary of the company's founding, a commemorative dividend of ¥40 per share will be paid in two installments during fiscal 2026: the year-end dividend for FY2026 (ending March 2026) and the interim dividend for FY2027 (ending March 2027).

Dividend

Paying

Share Buyback

Possible

Shareholder Benefits

None

ESG

The company has conducted climate change scenario analysis (1.5°C and 4°C scenarios) based on the TCFD framework, setting targets of a 42% reduction in CO2 emissions by FY2030 versus FY2020 and carbon neutrality by 2050. In terms of human capital, the company has set forth

Board Members

神澤陸雄

代表取締役会長最高経営責任者 (CEO)

竹花泰雄

代表取締役社長最高執行責任者 (COO)

福島敬二

取締役副社長

高山哲

専務取締役最高人事責任者(CHRO)

北原孝秀

常務取締役 最高財務責任者 (CFO)

降簱喜男

取締役相談役

野明浩史

取締役医薬営業本部長

宮澤敬治

取締役研究本部長

清水重孝

取締役

野村稔

取締役

内 川 小百合

取締役

大月良則

取締役

菊池伸次

常勤監査役

腰 原 なおみ

常勤監査役

中川寛道

監査役

岩渕道男

監査役

Last updated: July 19, 2026